Primary Myelofibrosis > Doxorubicin, Abiraterone, Bevacizumab, Nivolumab, Sunitinib, Tretinoin, Entrectinib, Losartan, Pembrolizumab, Sorafenib, Vemurafenib, Vismodegib, Abemaciclib, Bortezomib, Afatinib, Cobimetinib, Carboplatin, Darolutamide, Olaparib, Cabozantinib, Ponatinib, Cabazitaxel, Dabrafenib, Idelalisib, Oxaliplatin, Palbociclib, Erlotinib, Pertuzumab, Ruxolitinib, Trametinib, Bicalutamide, Dasatinib, Nab-paclitaxel, Neratinib, Fluorouracil, Capecitabine, Sirolimus, Durvalumab, Enasidenib, Everolimus, Leucovorin, Regorafenib, Dacomitinib, Imatinib, Trastuzumab Emtansine, Venetoclax, Ipilimumab, Lenvatinib, Lorlatinib, Celecoxib, Copanlisib, Vorinostat
Personalized Cancer Therapy for Cancer
Recruiting in Palo Alto (17 mi)
Overseen byZahi Mitri, MD, MS
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: OHSU Knight Cancer Institute
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
Eligibility Criteria
Adults over 21 with various advanced cancers, good performance status (able to carry out daily activities), and a life expectancy of at least 6 months. They must have normal organ function tests, no active infections or other cancers, not be on other experimental drugs, and agree to use contraception.Inclusion Criteria
My blood clotting time is normal or managed with medication.
Your platelet count is at least 100,000 per microliter within 4 weeks before starting the treatment.
My kidney function is within the normal range required.
+16 more
Exclusion Criteria
I do not have any other active cancer besides the one being treated.
Participants with medical conditions, inclusive of psychiatric, that in the opinion of the investigators would jeopardize the patient or the study will be excluded
My condition has worsened and I can't care for myself.
+10 more
Participant Groups
The SMMART PRIME trial is testing how different drug combinations affect individual cancer cases by analyzing patient samples. It aims to understand why treatments fail and how diverse cancers respond to varied therapies.
1Treatment groups
Experimental Treatment
Group I: Treatment (biospecimen collection, 2 drug combination)Experimental Treatment56 Interventions
TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.
SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health \& Science University (OHSU).
Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
OHSU Knight Cancer InstitutePortland, OR
Loading ...
Who Is Running the Clinical Trial?
OHSU Knight Cancer InstituteLead Sponsor
Oregon Health and Science UniversityCollaborator